Sandoz submits ANDA for Pemigatinib, seeking FDA approval
Sandoz Inc. has submitted an Abbreviated New Drug Application (ANDA) for Pemigatinib, currently under standard review.
Asset / Drug
Drug and asset intelligence for Pemigatinib with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.